Enquirer Consulting Group

Reachable Buyer Map

Prepared for Stephen Ball · The US market Phyton Biotech sells into · August 2026
In this category, first contact usually happens at the point of need: a sourcing team opens an inquiry, or a program lead calls the two or three names already on the shortlist. That reaches the buyers who are in the market this quarter. This map is the rest, counted across the United States only, which is where the largest concentration of these buyers sits rather than where the plant does. The segments that buy plant derived actives and contract fermentation capacity, who signs inside each one, and roughly how many companies sit there.
Biotechnology research and development companies
The largest tile and the one furthest upstream. These companies own molecules and almost no plant, so every step from process development to commercial supply is bought rather than built. The decision is made once per program and then rarely revisited.
Who signs: VP of CMC, head of technical operations, chief scientific officer, and at earlier stage companies the founder or CEO.
5,800 to 6,300
US employers registered in biotechnology research and development, of which roughly 1,900 carry 20 or more people on the plan
Pharmaceutical and biological product manufacturers
The segment that buys finished active ingredients directly, including the generic injectable makers whose economics turn on a qualified, documented source rather than on the lowest quoted number.
Who signs: head of external manufacturing, VP of global sourcing, head of supplier quality, director of API procurement.
4,200 to 4,600
US employers registered across pharmaceutical preparation and biological product production, of which roughly 2,100 carry 20 or more
Nutraceutical and dietary supplement makers
A market where a plant derived compound at consistent purity is the whole product claim. Buying cycles are far shorter here than in pharmaceuticals, and the technical conversation happens at the same table as the commercial one.
Who signs: VP of research and development, head of ingredient sourcing, chief operating officer, founder at owner run brands.
1,900 to 2,200
US employers registered across vitamin, supplement and nutraceutical production, of which roughly 900 carry 20 or more
Cosmetics, fragrance and personal care producers
Named on the Phyton site alongside pharmaceuticals. Natural origin and a traceable supply story now carry weight in this category, which turns a fermentation route into a marketing asset as well as a technical one.
Who signs: head of research and development, director of raw material sourcing, head of product innovation, technical director.
1,600 to 1,900
US employers registered across cosmetics, fragrance and personal care production, of which roughly 700 carry 20 or more
Flavor and specialty food ingredient producers
The buyers of botanical compounds where supply from harvested crops is seasonal and unstable. Anything that removes weather from the cost line gets a hearing, though qualification runs long.
Who signs: director of ingredient sourcing, head of research and development, VP of supply chain, technical sales lead.
1,100 to 1,300
US employers registered across flavor, extract and specialty food ingredient production, of which roughly 550 carry 20 or more
Medicinal and botanical extract producers
The smallest tile by count and the most mixed in intent. Some are competitors on the extraction route, some are partners who need a compound they cannot get from harvested material at the volume or purity they have promised.
Who signs: chief technical officer, head of operations, head of business development, owner.
700 to 850
US employers registered as medicinal and botanical producers, of which roughly 300 carry 20 or more

Where the openings are

1
The segments above come to roughly 15,300 to 17,150 registered US employers. About 6,450 of them carry 20 or more people on the plan, which is the band that can fund an outsourced development program rather than a bench experiment. In this category, inbound and shortlist contact reaches whoever is already looking this quarter. The rest is not unqualified, it is simply unaware.
2
The largest tile is the one bought lists under-work. Companies that own a molecule and outsource all of the making do not register as manufacturers, so a purchased list of pharmaceutical manufacturers reaches the plants and misses the programs. Reaching that layer takes identification rather than purchase, which is exactly why it stays open.
3
Four of these segments are not pharmaceutical at all. The Phyton site names herbal medicine, food and cosmetics alongside pharmaceuticals, and dietary supplements sit next door to all three. Those buyers sit under different sector codes and answer to different titles, and they will not be found by working the pharmaceutical list harder. One channel tends to keep returning to the same door.
4
The buyer here is a program, not a company. A contract manufacturing decision is made per molecule and per phase, and it reopens at specific moments: a second source qualification, a supply interruption, a program crossing from development into commercial supply. A channel built on named roles is what catches those moments. A channel built on inbound hears about them after the inquiry has closed.
Built from public federal registry data covering US employers that file a benefit plan, current to the 2024 filing year. Counts are banded deliberately. Workforce bands use plan participants as a headcount proxy, so they indicate scale rather than an exact staff count. Owner-only and very small employers are not published in this data. Sector codes are self-reported by the companies themselves. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com